FOCUSING on IMPROVING THE LIVES of PATIENTS

WITH DIFFICULT-TO-TREAT DISEASES

RECENT NEWS

BioMed Valley Discoveries and collaborators recently published an article summarizing preclinical studies of first-in-class ERK-targeted cancer therapy ulixertinib (BVD-523) in Molecular Cancer Therapeutics.

October 3, 2017

COMBINING the EXPERTISE of our TEAM and our PARTNERS to BREAK THROUGH BARRIERS in EARLY STAGE DRUG DEVELOPMENT